Cantor Fitzgerald began coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH – Free Report) in a research note issued to investors on Thursday, Marketbeat reports. The firm issued an overweight rating on the stock. Cantor Fitzgerald also issued estimates for Dianthus Therapeutics’ FY2024 earnings at ($2.54) EPS.
Several other analysts also recently issued reports on DNTH. HC Wainwright started coverage on Dianthus Therapeutics in a report on Thursday, May 16th. They issued a buy rating and a $40.00 price target for the company. Raymond James raised their target price on Dianthus Therapeutics from $34.00 to $51.00 and gave the company an outperform rating in a report on Thursday, April 18th. Wedbush boosted their price target on Dianthus Therapeutics from $33.00 to $38.00 and gave the stock an outperform rating in a research report on Friday, May 10th. Jefferies Financial Group increased their price objective on shares of Dianthus Therapeutics from $22.00 to $39.00 and gave the company a buy rating in a research report on Friday, March 22nd. Finally, Lifesci Capital raised shares of Dianthus Therapeutics to a strong-buy rating in a research report on Tuesday, June 11th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of Buy and a consensus target price of $42.83.
Read Our Latest Research Report on DNTH
Dianthus Therapeutics Price Performance
Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.11). The business had revenue of $0.87 million for the quarter, compared to analysts’ expectations of $0.48 million. Research analysts anticipate that Dianthus Therapeutics will post -2.18 EPS for the current year.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC bought a new stake in shares of Dianthus Therapeutics in the 4th quarter worth about $25,000. Citigroup Inc. acquired a new position in Dianthus Therapeutics in the third quarter worth about $53,000. Acadian Asset Management LLC bought a new stake in Dianthus Therapeutics in the third quarter valued at about $303,000. Virtu Financial LLC bought a new stake in Dianthus Therapeutics in the first quarter valued at about $390,000. Finally, Laurion Capital Management LP acquired a new stake in Dianthus Therapeutics during the third quarter valued at approximately $497,000. 47.53% of the stock is currently owned by institutional investors.
Dianthus Therapeutics Company Profile
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Featured Articles
- Five stocks we like better than Dianthus Therapeutics
- 5 discounted opportunities for dividend growth investors
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- What does consumer price index measure?
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- 3 Healthcare Dividend Stocks to Buy
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.